Financial Performance - Total revenue for the year ended December 31, 2023, was RMB 331,308,000, an increase of 2.9% compared to RMB 323,374,000 in 2022[3]. - Gross profit for the year was RMB 29,895,000, down 8.1% from RMB 32,552,000 in the previous year[3]. - The company reported a net loss of RMB 96,091,000 for the year, compared to a net loss of RMB 93,743,000 in 2022, reflecting a 2.4% increase in losses[3]. - Basic and diluted loss per share for the year was RMB 49.15, compared to RMB 48.01 in the previous year[3]. - The total comprehensive loss for the year was RMB 80,192,000, an improvement from RMB 99,506,000 in 2022[3]. - The group reported a pre-tax loss of RMB 96,378,000 for 2023, compared to a loss of RMB 91,035,000 in 2022, indicating a year-over-year increase in losses of approximately 4.9%[19]. - The group recognized an impairment loss of approximately RMB 20.4 million for intangible assets in the current year, compared to no impairment loss for the year ended December 31, 2022[72]. - The group reported a tax expense of RMB 24,094,000 for 2023, compared to RMB 22,759,000 in 2022, reflecting an increase in tax liabilities[32]. Revenue Breakdown - Revenue from medical consultation services was RMB 163,680,000 in 2023, down from RMB 166,760,000 in 2022, reflecting a decrease of approximately 1.3%[21]. - The group generated RMB 5,612,000 from patient education and self-testing services in 2023, a significant decline from RMB 28,554,000 in 2022, marking a decrease of about 80.3%[21]. - The revenue from sales strategy consulting services increased to RMB 136,801,000 in 2023, up from RMB 102,977,000 in 2022, showing a growth of approximately 33%[21]. - Revenue from marketing strategy and consulting services rose by approximately 32.8% from about RMB 103.0 million to approximately RMB 136.8 million, attributed to the postponement of projects due to the COVID-19 pandemic[60]. - CRO services revenue increased by approximately 81.4% from about RMB 6.4 million to approximately RMB 11.7 million, driven by an increase in users and demand post-pandemic[64]. - Revenue from digital marketing solutions decreased by approximately 28.1% from about RMB 14.6 million to approximately RMB 10.5 million, primarily due to a slowdown in demand[61]. - Revenue from internet hospital services decreased by approximately 24.9% from about RMB 4.0 million to approximately RMB 3.0 million, mainly due to tightened regulations in China[65]. Expenses and Costs - Research and development expenses decreased to RMB 32,685,000, a reduction of 35.4% from RMB 50,612,000 in 2022[3]. - The company recorded a decrease in selling expenses to RMB 22,335,000, down 12.6% from RMB 25,476,000 in 2022[3]. - Administrative expenses increased slightly to RMB 51,014,000, compared to RMB 50,087,000 in the previous year[3]. - Employee costs increased to RMB 96,425,000 in 2023 from RMB 94,597,000 in 2022, reflecting a rise of approximately 1.9%[26]. - The total employee benefits, including salaries and retirement benefits, amounted to RMB 73,654,000 in 2023, up from RMB 69,863,000 in 2022[26]. - The financial cost for 2023 was RMB 1,304,000, slightly higher than RMB 1,246,000 in 2022, representing an increase of about 4.7%[25]. Assets and Liabilities - Total assets decreased from RMB 317.826 billion in 2022 to RMB 214.318 billion in 2023, a decline of approximately 32.6%[4]. - Total liabilities decreased from RMB 108.076 billion in 2022 to RMB 92.271 billion in 2023, a reduction of about 14.7%[5]. - The net value of total assets after deducting current liabilities decreased from RMB 209.750 billion in 2022 to RMB 122.047 billion in 2023, a decrease of approximately 41.8%[5]. - The company's cash and cash equivalents decreased from RMB 138.571 billion in 2022 to RMB 80.352 billion in 2023, a decline of about 42.0%[4]. - The company's total equity decreased from RMB 200.859 billion in 2022 to RMB 119.967 billion in 2023, a decline of about 40.2%[5]. - The company's current liabilities, including trade payables, decreased from RMB 34.021 billion in 2022 to RMB 32.297 billion in 2023, a reduction of approximately 5.1%[5]. Strategic Focus and Future Plans - The company plans to focus on market expansion and new product development in the upcoming year[2]. - The company is focused on strategic management and operational efficiency to navigate the current financial landscape[7]. - The company aims to enhance digital pharmaceutical market services through data analysis for improved service quality and efficiency[42]. - The company is committed to high-quality development and innovation-driven growth in response to global economic trends[41]. - The company aims to enhance digital and intelligent innovations in medical services in 2024, focusing on improving service quality and expanding business scale[55]. - The company plans to further expand its innovative smart medical and digital healthcare services in 2024 by collaborating with more hospitals and leveraging digital technology to enhance treatment standardization[50]. Digital Transformation and Technology - The company is focusing on leveraging AI technology and web 3.0 digital technology for business innovation and growth[42]. - The company successfully applied AI-generated content (AIGC) technology across its platforms, enhancing patient education services and improving communication efficiency between doctors and patients[43]. - The launch of web 3.0 digital technology in November 2023 aims to assist physicians in establishing digital assets and provide a platform for rights confirmation and transaction of medical content[45]. - The integration of the Long Neck Deer Internet Hospital platform and the Medical Management platform will provide more effective digital content and clinical decision support systems for healthcare institutions[51]. - The company has established deep connections with physicians and patients through new tools like apps and WeChat, facilitating the provision of medical knowledge and health management services[46]. Governance and Compliance - The company has adopted good corporate governance principles and complies with the new listing rules effective until December 31, 2023[112]. - The audit committee, consisting of three independent non-executive directors, has reviewed the group's annual performance for the year ending December 31, 2023[117]. - The annual performance announcement and annual report will be published on the Hong Kong Stock Exchange and the company's website[120].
麦迪卫康(02159) - 2023 - 年度业绩